The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study

Angela Horvath1,2*, Bettina Leber3, Nicole Feldbacher1,2, Markus Steinwender4, Irina Komarova1, Florian Rainer1, Andreas Blessler1 & Vanessa Stadlbauer1

Side effects of proton pump inhibitors (PPI) can be linked to the changes in the intestinal microbiota that occur during therapy, especially in long-term users. Therefore, the microbiota might also be a key player in the reduction of PPI side effects. We tested the effects of a three-month intervention with a multispecies synbiotic on intestinal inflammation, gut barrier function, microbiome composition, routine laboratory parameters and quality of life in patients with long-term PPI therapy. Thirty-six patients received a daily dose of a multispecies synbiotic for three months and were clinically observed without intervention for another three months. After intervention 17% of patients reached normal calprotectin levels; the overall reduction did not reach statistical significance (−18.8 ng/mg; 95%CI: −50.5; 12.9, p = 0.2). Elevated zonulin levels could be significantly reduced (−46.3 ng/mg; 95%CI: −71.4; −21.2; p < 0.001). The abundance of Stomatobaculum in the microbiome was reduced and Bacillus increased during the intervention. Furthermore, albumin, alkaline phosphatase and thrombocyte count were significantly increased and aspartate transaminase was significantly decreased during intervention. Gastrointestinal quality of life showed significant improvements.

In conclusion, microbiome-related side effects of long-term PPI use can be substantially reduced by synbiotic intervention. Further studies are warranted to optimize dosage and duration of the intervention.

In the last 30 years proton pump inhibitors (PPI) have established themselves as highly effective treatment of acid related diseases and became the most often prescribed class of drugs in gastroenterology1,2. Underneath their immaculate image of gastric protection, however, their side effect profile - although well described by high quality data - remained largely unaddressed3. Many of the side effects might be rooted in PPI-induced changes of the microbiome (i.e. dysbiosis): increased risk of enteric infections, bloating, flatulence, abdominal pain, stool frequency abnormalities, intestinal inflammation and vitamin B12 malabsorption4–12.

Long term PPI use can introduce ample alterations to the intestinal microbiome: Changes in composition, reduction of alpha diversity, small intestinal bacterial overgrowth and the manifestation of oral bacteria in more distal parts of the intestine have been observed13–19. A loss of alpha diversity and therefore a loss in pathogen-colonization resistance could account for the increased risk of enteric infections20,21. The change of composition, which includes the reduction of Clostridiales and the increase of Enterococcaceae and Streptococcaceae, and function of the microbiota might directly predispose for Clostridium difficile infections22. In children, persistent bowel symptoms during PPI use have been linked to small intestinal bacterial overgrowth23. The association with the microbiota could be a crucial factor for the amelioration of PPI side effects. Modulating the microbiota with probiotic bacteria might be able to reduce the burden of side effects during PPI therapies. The merit of this idea has been shown in a trial administering Lactobacillus reuteri together with PPI that could successfully reduce small intestinal bacterial overgrowth in children24. Probiotics also have additional effects of which PPI-treated patients could profit: they have been shown to reduce pathogen growth and drug-induced diarrhoea, ameliorate bowel symptoms, and improve gut barrier and liver function in previous reports25–35. Furthermore, the use of...
Prebiotics (i.e. indigestible dietary fibre) or synbiotics (i.e. combination of probiotics and synbiotics) can support the resident microbiome and complement the effects of probiotic supplementation. However, since PPI-specific data is still scarce, the routine use of probiotics during PPI therapy is not recommended yet.

Therefore, we tested the hypothesis that the administration of probiotics reduces PPI side effects. We aimed to show the effects of a three-month intervention with a multispecies synbiotic on intestinal inflammation, gut barrier function, microbiome composition, routine laboratory parameters and gastrointestinal quality of life in patients with long-term PPI therapy.

Results

Patients. Fifty-seven patients with long-term PPI use were screened for the study; eight patients did not meet the inclusion/exclusion criteria (declined to participate: n = 5; PPI therapy too short: n = 2; active infection: n = 1). Forty-nine patients started the intervention and 36 finished it according to the protocol. Reasons for drop-out were withdrawn consent (n = 8), side-effects (gastric pain: n = 1; gastrointestinal discomfort: n = 2; constipation: n = 1) and liver transplantation (n = 1). See also Fig. 1. Patients were on average 63 years (95% CI: 59; 67) old, 47% were female and the average duration of PPI therapy was 63 months (95% CI: 44; 82). Reasons for PPI therapy were peptic ulcer/reflux disease (n = 21), polypharmacy (n = 8) and others (n = 7). Of the 36 analyzed patients, twelve had liver cirrhosis (details are given in Table S1). Patients stayed on their PPI regime throughout the study and did not make substantial changes to their diet. Patients’ characteristics are given in Table 1.

| Analyzed patients (n = 36) |
|---------------------------|
| Age (years) | 63 (59; 67) |
| Sex (f/m) | 17/19 (47/53%) |
| Duration of PPI (months) | 63 (44; 82) |
| PPI regime: | |
| Pantoprazole | 24 (67%) |
| −20 mg | 3 (8%) |
| −40 mg | 20 (56%) |
| −60 mg | 1 (3%) |
| Esomeprazole | 7 (19%) |
| −20 mg | 2 (5%) |
| −40 mg | 5 (14%) |
| others | 5 (14%) |
| Reason for PPI: | |
| Peptic Ulcer/Reflux | 21 (58%) |
| Drug use/Polypharmacy | 8 (22%) |
| others | 7 (20%) |
| Cirrhosis (yes/no) | 12/24 (50/50%) |

Table 1. Characteristics of patients included in the analysis. (PPI: proton pump inhibitor).
was no change in lipopolysaccharide, lipopolysaccharide-binding protein or sCD14 levels. For details see Table 2.

When patients with elevated and normal zonulin levels were analyzed together, the reduction did not reach statistical significance (p = 0.57) of patients with initially increased calprotectin levels showed a reduction of at least 10% after intervention. In total, 57% of patients with initially increased calprotectin levels showed a reduction of at least 10% after intervention. Details are given in Table 2.

Since one third of the study cohort had liver cirrhosis as underlying disease, liver cirrhosis was analyzed as a potential confounder. Calprotectin levels were significantly higher in patients with cirrhosis as shown in Table S1, and the mean decrease after synbiotic intervention was larger in cirrhotic patients compared to liver healthy patients, although not statistically significant (−35.9 ng/mg (95%CI: −129.0; 57.2) vs. −10.2 ng/mg (95%CI: −32.9; 12.4), respectively, p = 0.07).

Intestinal inflammation. Fecal calprotectin levels at baseline were elevated to 147.1 ng/mg (95%CI: 106.4; 187.8) and decreased on average by 18.8 ng/mg (95%CI: −50.5; 12.9, p = 0.2) during the intervention. Thirty patients (83%) had elevated calprotectin levels (i.e. >50 ng/mg) at baseline. Of these 30 patients, five (17%) showed normal calprotectin levels after the intervention, and therefore reached the primary endpoint. In total, 57% of patients with initially increased calprotectin levels showed a reduction of at least 10% after intervention. Details are given in Table 2.

Since one third of the study cohort had liver cirrhosis as underlying disease, liver cirrhosis was analyzed as a potential confounder. Calprotectin levels were significantly higher in patients with cirrhosis as shown in Table S1, and the mean decrease after synbiotic intervention was larger in cirrhotic patients compared to liver healthy patients, although not statistically significant (−35.9 ng/mg (95%CI: −129.0; 57.2) vs. −10.2 ng/mg (95%CI: −32.9; 12.4), respectively, p = 0.07).

Gut permeability. Fecal zonulin levels were slightly increased at baseline (60.9 ng/mg, 95%CI: 44.4; 77.5) with 44% of patients showing increased levels (i.e. >50 ng/mg). Patients with zonulin levels >50 ng/mg at baseline showed significant reduction of −46.3 ng/mg (95%CI: −71.4; −21.2, p < 0.001) during intervention and maintained low zonulin levels for three months after intervention had ended. When patients with elevated and normal zonulin levels were analyzed together, the reduction did not reach statistical significance (p = 0.4). There was no change in lipopolysaccharide, lipopolysaccharide-binding protein or sCD14 levels. For details see Table 2. Zonulin levels at baseline were similar in patients with and without liver cirrhosis and both groups showed comparable decrease during synbiotic intervention (−18.8 ng/mg (95%CI: −55.8; 18.25) vs. −5.2 ng/mg (95%CI: −24.5; 14.1), respectively, p = 0.5).

Gut microbiome. Patients showed microbiome changes consistent with the literature. Compared to a published control cohort, alpha diversity of patients before the intervention was significantly reduced (Chao1: p < 0.001). See also Fig. S1A. Beta diversity was significantly influenced by PPI use as assessed by redundancy analysis (RDA: Variance = 26.26, F = 1.7, p = 0.001) and shown in Fig. S1B. Since one third of the study cohort had liver cirrhosis as underlying disease, liver cirrhosis was analyzed as a potential confounder. Alpha diversity was not significantly different between patient groups, although liver healthy patients showed a somewhat higher Chao1 index as cirrhotic patients (p = 0.07). Beta diversity showed slight changes between the groups (RDA: Variance = 20.04, F = 1.3, p = 0.04). Details are given in Fig. S2. When underlying disease was used as a confounder in LEfSe analysis, PPI users still showed a significantly higher abundance of oral bacteria, such as Streptococcus, Lactobacillus, Veillonella and Rothia compared to controls (full list is provided in Fig. S2). Microbiome composition was not substantially changed after synbiotic intervention. There was no change in alpha diversity as shown in Fig. 2a (Chao1: p = 0.8). Redundancy analysis showed no specific clustering of samples before and after intervention (p > 0.999, Fig. 2b) and no distinct networks could be identified for the two time points. LEfSe attributed the genus Stomatobaculum to samples before intervention and the genus Bacillus to samples after intervention (Fig. 2c). In addition, the family Bacillaceae and an operational taxonomic unit identified as Bacillus coagulans were significantly increased after intervention (p < 0.001 and p = 0.001, respectively). Bacillus coagulans was part of the synbiotic formulation used in this study. The other probiotic strains did not show a significant increase during intervention using 16S rRNA gene sequencing technology (Fig. 2d).

Table 2. Baseline values and changes in biomarkers for intestinal inflammation and permeability, liver function and Vitamin B12 levels throughout the study; data are given as mean (95% confidence interval), \(^{a}\)all patients, \(^{b}\)selected patients with increased baseline values.

| Biomarker                                | Before Intervention | After Intervention | Follow up | p-value (Before vs. After) | p-value (Before Intervention vs. Follow-up) |
|------------------------------------------|---------------------|--------------------|-----------|---------------------------|---------------------------------------------|
| Calprotectin (ng/mg)                     | 147.1 (106.4; 187.8)| 128.3 (92.1; 164.5)| 142.9 (107.3; 178.4)| 0.192                     | —                                           |
| - when >50 ng/mg at baseline             | 168.7 (123.7; 213.7)| 142.6 (101.0; 184.2)| 161.5 (122.1; 200.9)| 0.090                     | —                                           |
| Zonulin (ng/mg)                          | 60.9 (44.4; 77.5)   | 51.2 (41.8; 60.6)  | 51.9 (40.0; 63.8)  | 0.385                     | —                                           |
| - when >50 ng/mg at baseline             | 100.1 (73.8; 126.4) | 53.8 (41.5; 66.0)  | 48.7 (33.7; 63.8)  | <0.001                    | 0.007                                       |
| Lipopolysaccharide (EU/ml)               | 1.9 (0.9; 2.9)      | 1.6 (0.9; 2.3)     | 2.3 (1.2; 3.4)     | 0.428                     | —                                           |
| Lipopolysaccharide-binding protein (ng/ml)| 14.8 (12.3; 17.2)  | 14.6 (12.8; 16.4)  | 12.9 (10.9; 15.0)  | 0.561                     | —                                           |
| sCD14 (µg/ml)                            | 2.3 (2.1; 2.6)      | 2.5 (2.2; 2.8)     | 2.1 (1.9; 2.2)     | 0.177                     | —                                           |
| Albumin (g/dl)                           | 4.1 (4.0; 4.2)      | 4.2 (4.1; 4.3)     | 4.2 (4.1; 4.4)     | 0.027                     | 0.013                                       |
| Alanine aminotransferase (U/l)           | 29.3 (24.2; 34.3)   | 27.8 (23.4; 32.1)  | 25.5 (22.4; 28.7)  | 0.317                     | —                                           |
| Aspartate transaminase (U/l)             | 32.0 (27.9; 36.1)   | 29.1 (25.2; 33.1)  | 28.1 (23.9; 32.3)  | 0.016                     | 0.005                                       |
| Alkaline Phosphatase (U/l)               | 76.1 (67.0; 85.1)   | 79.9 (70.9; 89.0)  | 79.6 (69.5; 89.7)  | 0.004                     | 0.006                                       |
| Thrombocytes (G/l)                       | 196 (163; 229)      | 207 (174; 240)     | 216 (185; 247)     | 0.010                     | 0.138                                       |
| PZINR                                    | 1.1 (1.0; 1.2)      | 1.1 (1.0; 1.2)     | 1.0 (0.9; 1.1)     | 0.695                     | —                                           |
| Vitamin B12 (ng/l)                       | 406 (355; 457)      | 416 (362; 469)     | 445 (382; 508)     | 0.784                     | —                                           |
| C-reactive proteins (mg/l)               | 3.4 (2.0; 4.9)      | 3.0 (2.1; 3.9)     | 3.8 (2.2; 5.5)     | 0.388                     | —                                           |
Biochemical parameters. Albumin concentration increased significantly (+0.08 g/dl, 95%CI: 0.01; 0.15; p = 0.03) and aspartate transaminase (AST) concentration decreased significantly after treatment (−2.9 U/l, 95% CI: −5.7; −0.1; p = 0.02). Alkaline phosphatase (AP) increased significantly, however within the normal range (+3.9 U/l, 95% CI: 1.2; 6.5; p = 0.004). Changes in albumin, AST and AP were sustained throughout the follow-up period. Thrombocyte count increased slightly after intervention (+11.3 G/l, 95% CI: 3.3; 19.3; p = 0.01) but did not exceed the normal range in any case. Thrombocyte count at follow up was unchanged compared to baseline values. Vitamin B12 did not show any changes, however none of the patients had a vitamin B12 deficiency. None of the other biochemistry results were affected by synbiotic intervention. Details are given in Table 2.

AST and AP were significantly higher, and albumin and thrombocyte count were significantly lower in patients with cirrhosis as expected (see Table S1). Nevertheless, mean changes from baseline were comparable between patients with and without cirrhosis (Albumin: 0.05 g/dl (95%CI: −0.06; 0.2) vs. 0.1 g/dl (95%CI: 0.01; 0.2), respectively, p = 0.5; AST: −2.0 U/l (95%CI: −9.8; 5.8) vs. −3.3 U/l (95%CI: −5.7; −0.9), respectively, p = 0.5; AP: 4.6 U/l (95%CI: −0.2; 9.4) vs. 3.5 U/l (95%CI: 0.06; 6.9), respectively, p = 0.6; thrombocyte count: 7.2 G/l (95%CI: 0.5; 13.9) vs. 13.3 G/l (95%CI: 1.6; 24.9), respectively, p = 0.4).
biome composition due to the intervention were minimal after three months. Two genera were differentially
exercise-induced protein oxidation was observed30. Also, perioperative interventions with multispecies probiot-
α
week long intervention with a multispecies probiotic. Simultaneously, a decrease in TNF
stopped. The regulatory mechanism of probiotics on zonulin levels have been shown in trained men after a 14
parameters and quality of life; however intestinal inflammation and microbiome composition were unchanged.
Table 3. Changes in gastrointestinal and health related quality of life throughout the study; data are given as mean (95% confidence interval). (GIQLI: gastrointestinal quality of life index; SF36: Short Form 36).

Quality of life. Gastrointestinal quality of life index (GIQLI) improved significantly during the intervention (total score: +8.9 points, 95%CI: 4.0; 13.8, p = 0.001). This was mainly facilitated by an improvement in quality of life related to symptoms and emotions which showed an increase of 4.5 points (95%CI: 1.8; 7.3, 0.002) and 1.2 points (95%CI: 0.3; 2.1, p = 0.01), respectively. While quality of life related to emotions returned to baseline values three months after the intervention had ended, quality of life related to gastrointestinal symptoms remained improved until the end of the follow-up period. The short-form (SF) 36 items and the remaining items of GIQLI remained unchanged throughout the study period. For details see Table 3.

Cirrhosis did not affect GIQLI scores and their average improvements during synbiotic intervention were comparable between patients with and without cirrhosis (total score: 9.6 points (95%CI: −0.6; 19.7) vs. 8.6 points (95%CI: 2.6; 14.6), respectively, p = 0.6; symptoms: 4.8 points (95%CI: −1.5; 9.9) vs. 4.7 points (95%CI: 1.3; 8.1), respectively, p = 0.9; emotions: 0.5 points (95%CI: −1.1; 2.0) vs. 1.6 points (95%CI: 0.47; 2.7), respectively, p = 0.4).

Discussion

This study shows that a multispecies synbiotic containing twelve strains has the potential to improve PPI side effects after three months of intervention. We observed improvements in gut permeability, liver biochemistry parameters and quality of life; however intestinal inflammation and microbiome composition were unchanged.

Calprotectin levels were increased in the study patients, who were all free of any inflammatory bowel disease. This confirms previous reports that linked PPI use and PPI-associated changes in the microbiome to increased calprotectin levels, irrespective of underlying conditions11,12,27. Although some improvement in intestinal inflammation was observed, the primary endpoint that was defined as a normalization of elevated calprotectin levels was not reached. We were able to achieve a 10% reduction of calprotectin levels in 57% of the patients. It is yet unclear whether calprotectin needs to normalize in order to prevent PPI induced side effects or if a reduction will also provide clinical benefits. Since the average duration of PPI therapy was 63 months, a three-month synbiotic intervention during ongoing PPI treatment might also be too short to ameliorate inflammatory conditions.

On the other hand, zonulin levels were responsive to the intervention and, when elevated at baseline, showed significant reduction after three months and did not increase three months after the synbiotic intervention had stopped. The regulatory mechanism of probiotics on zonulin levels have been shown in trained men after a 14 week long intervention with a multispecies probiotic. Simultaneously, a decrease in TNFα and a reduction of exercise-induced protein oxidation was observed30. Also, perioperative interventions with multispecies probiotics in patients with colorectal cancer and/or colorectal liver metastases could reduce zonulin levels and reduce post-operative bacterial translocation, infectious events and duration of antibiotic therapy38,39. A probiotic intervention in cirrhosis failed to reduce zonulin levels after three and six months40, however, patients’ zonulin levels in that study were comparable to healthy controls. A recent report linked zonulin levels in cirrhosis to PPI-associated dysbiosis27.

Dysbiosis is well described in PPI users; the main features are a loss in diversity, oralization and small intestinal bacterial overgrowth13–15,18. Patients in our study exhibited typical changes in the composition of their microbiome compared to healthy controls without PPI use (details are given as Supplementary Information). Foremost, the increase in predominantly oral bacteria (i.e. oralization), including Streptococcus, Veillonella, Rothia, among others, is evident, as it has been described previously for PPI users15,27. Furthermore, the decrease of beneficial genera has been observed in our patients in accordance to the literature17,19. Unfortunately, changes in the microbiome composition due to the intervention were minimal after three months. Two genera were differentially

|                  | Before Intervention | After Intervention | Follow up | p-value (Before vs. After) | p-value (Before Intervention vs. Follow-up) |
|------------------|---------------------|--------------------|-----------|---------------------------|--------------------------------------------|
| GIQLI            |                     |                    |           |                           |                                            |
| Emotions         | 14 (12; 15)         | 15 (14; 17)        | 14 (13; 16) | **0.010**                 | 0.719                                      |
| Medical function | 3 (3; 4)            | 4 (3; 4)           | 3 (3; 3)  | 0.101                     |                                            |
| Physical function| 16 (13; 18)         | 17 (16; 19)        | 16 (14; 18) | 0.089                     |                                            |
| Social function  | 12 (11; 13)         | 13 (12; 14)        | 11 (10; 12)| 0.060                     |                                            |
| Symptoms         | 54 (50.57)          | 58 (55; 61)        | 55 (52 (59)| **0.002**                 | 0.028                                      |
| Total score      | 98 (92; 105)        | 107 (101; 113)     | 100 (93; 107) | **0.001**                 | 0.159                                      |
| SF-36            |                     |                    |           |                           |                                            |
| General health   | 58 (51; 66)         | 57 (51; 64)        | 52 (45; 59)| 0.600                     |                                            |
| Social role      | 80 (67; 92)         | 85 (74; 96)        | 76 (61; 91)| 0.507                     |                                            |
| Physical role    | 65 (51; 80)         | 58 (43; 73)        | 55 (38; 72)| 0.233                     |                                            |
| Bodily pain      | 60 (50; 71)         | 67 (58; 76)        | 53 (43; 64)| 0.124                     |                                            |
| Physical functioning | 75 (67; 82)  | 76 (69; 82)        | 66 (59; 74)| 0.688                     |                                            |
| Mental health    | 70 (62; 77)         | 73 (66; 79)        | 69 (62; 75)| 0.263                     |                                            |
| Social functioning| 79 (71; 88)         | 85 (77; 92)        | 73 (64; 83)| 0.101                     |                                            |
| Vitality         | 54 (46; 61)         | 57 (51; 62)        | 50 (43; 57)| 0.492                     |                                            |
abundant between the time points, *Stomatobaculum* and *Bacillus*. *Stomatobaculum* is an anaerobic bacterium from dental plaques⁶¹. The occurrence of this bacterium in stool can be a sign of oralization of the intestinal microbiome during PPI use. The abundance of *Stomatobaculum* was reduced during the intervention which might hint towards a potential role of probiotics in correcting PPI-induced dysbiosis (i.e. oralization), although *Stomatobaculum* is not a very prevalent oral taxon found in the intestinal microbiome of PPI users.

*Bacillus* increased during intervention, probably due to *Bacillus coagulans* that was ingested with the study product. Out of the twelve probiotic strains, only *Bacillus coagulans* was significantly increased. We were previously able to recover more strains in stool of patients with liver cirrhosis who used Ecologic Barrier/OmniBiotic Hetox (Winclove, Amsterdam, The Netherlands/Institut Allergosan Graz, Austria) - a product that shares 7 strains with the product under investigation in this study⁶². The reason for this difference is still elusive. The formulation and concentration of the study products differ between trials as well as the duration of intervention and the patient collective. Probiotic formulations have a wide range of bacterial content and evidence for dose dependent effects is still scarce⁶³. Different formulations have different minimum concentrations to be effective; in irritable bowel syndrome, *B. infantis* 35624 could reduce symptoms at a daily dose of 10⁸ CFU while higher dosages did not bring any additional benefit⁶⁴. Other formulations on the other hand, do show dose dependent increases in efficacy⁶⁵. The daily dose of bacteria in the study product with a total bacterial load of 8 × 10⁹ was lower than other popular probiotics such as the original VSL#3 (Alphasync, Covington, USA) or Ecologic Barrier (Winclove, Amsterdam, The Netherlands). These formulations contain 5 × 10¹¹ and 1.5 × 10¹⁰ CFU per dose respectively and consist of eight/nine distinctive probiotic strains compared to twelve strains in the study product⁶⁶. It is therefore possible that the concentration of each individual strain was too low to be detected by the sequencing effort in this study. Whether a higher dose of the study product could intensify the effects in patients with long-term PPI therapy, can only be clarified in future studies.

Furthermore, we observed a slight but significant increase in albumin levels and a decrease in the levels of the liver enzyme AST. The positive effects of probiotics on AST in non-alcoholic fatty liver disease are well documented⁶⁷,⁶⁸. Moreover, probiotic interventions in patients with and without different liver diseases were also attested a significant reduction of AST⁶⁹. Albumin is an indicator for liver function and for the absence of inflammation. Besides liver function, albumin also reflects the nutritional status of a patient. However, nutritional habits stayed unchanged throughout the study and the patients were all well-nourished, excluding nutrition as a possible reason for the increase in albumin in this study. Alkaline phosphatase also increased significantly during the intervention and higher levels were sustained during the follow-up period. Only 3/36 measurements were outside the normal range at the end of intervention, all 3 were within 1.5x of the upper limit of normal and gamma-glutamyl-transferase did not increase. This excludes cholestatic liver damage as possible source for the increase in AP. Human AP in serum is a mixture of several isoenzymes with different functions and AP levels can also be influenced by age, diet and various diseases⁷⁰. Serum AP outside the normal range has been associated with higher mortality⁷¹,⁷². However, other studies show that AP can also exert beneficial effects. In animal models of nercotizing ileocolitis, intestinal AP administration could reduce systemic inflammation⁷³ and protect gut barrier function in neonatal rats⁷⁴. Moreover, *in-vitro* studies have indicated intestinal AP in the up-regulation of tight junction proteins⁷⁵. Recombinant AP is under investigation to prevent sepsis-associated acute kidney injury in humans⁷⁶, however, the phase II study failed to show a clinical benefit⁷⁷. In addition to mammalian isoenzymes, several probiotic strains in the study product have shown substantial AP activity, which might contribute to the detoxification of lipopolysaccharide⁷⁸. Whether these enzymes translocate through the intestinal barrier and contribute to the total serum AP activity is not clear. A more comprehensive study of AP isoenzymes is warranted to answer this question. Taken together the changes in AST and albumin speak to the hepatoprotective effect of probiotics that has been indicated in previous reports⁷⁹,⁸⁰,⁸¹.

Quality of life is an important outcome assessor and reflects the impact of health care interventions on the patients’ everyday life and well-being⁸²,⁸³. The improvement in quality of life in the present study was based on a reduction of bowel symptoms and negative emotions. This reflects previously shown positive effects of probiotics on bowel symptoms in irritable bowel syndrome and functional bowel disorder⁸⁴–⁸⁶. *Bacillus coagulans* as a single-strain synbiotic formulation has been shown to reduce abdominal pain and diarrhea in irritable bowel syndrome patients⁸⁶. *Bacillus coagulans* was also the most prominent probiotic strain in the presented study, which sparks interest in the modes of action of this probiotic bacterium. The microbiome can influence quality of life and features of depression, and the potential to improve sad mood by modulating the microbiome with probiotics has been demonstrated before⁸⁷,⁸⁸. This is in accordance to the improved quality of life in regards to emotions that has been observed in the presented study. There were no changes in quality of life measured with the SF-36, although both questionnaires deal with patients’ emotions. A previous report by Shi et al. found that even though both instruments show validity on their own and there are clear correlation between the outcomes of the two instruments, GIQLI showed superior responsiveness in regards to emotional well-being in patients with cholecystectomy⁸⁹. It, therefore, seems to be more suitable for studying the impact of interventions in gastrointestinal diseases. Regardless of the questionnaire, quality of life is a subjective measure and the effects observed in this study need to be validated in a blinded, controlled trial.

To our knowledge this is the first study analyzing the effect of a synbiotic intervention on intestinal inflammation, gut permeability, microbiome composition, liver function and quality of life in long term PPI users. So far only one small study addressed the effect of probiotics in children receiving a 12 week treatment with PPI for gastroesophageal reflux. In this study no microbiome sequencing data were presented, but small intestinal bacterial overgrowth (measured with a hydrogen breath test) could be reduced significantly⁹⁰.

The foremost limitation of this study is the design as open labelled, uncontrolled trial. To our knowledge comparable trials in adults to address PPI-induced dysbiosis are missing. Therefore, a pilot trial was necessary on which decisions about endpoint and sample size for a full-sized randomized control trial can be based. A full-sized randomized control trial without pilot data would not have been economically feasible. This trial was
supposed to detect potential targets for symbiotic interventions in patients with long-term PPI use, in order to inform upcoming trials by us and others. The primary and many of the secondary endpoints are hard endpoints likely not influenced by the lack of a placebo control; however, the chosen trial design limits the interpretation of the more subjective measures, such as quality of life. The dropout rate of 27% was higher than expected (20%). Adverse effects related to abdominal discomfort accounted for one third of drop-outs. Since we performed the study as an open-label pilot trial, we are not able to discuss the relation of the product to the side effects. In a previous study using a multispecies probiotic containing 9 strains (7 of which are also present in the study product of this study) a much lower dropout rate (2%) and no side effects were observed in the treated group; in the placebo group the drop-out rate was 23%40. Generally, there is little information about the side-effect profile of individual strains, therefore a meaningful discussion about adverse effects of specific probiotics in this and other trials is not yet possible and comprehensive studies are warranted.

In conclusion: Symbiotic interventions have the potential to improve side effects of long-term PPI therapy in cirrhotic and liver healthy patients. Future studies are necessary to validate the here presented benefits and may find valuable therapeutic targets in gut permeability, liver function parameters and quality of life.

Methods
Between September 2017 and March 2018 an open-label pilot trial was conducted at the University Hospital Graz/Austria (Division of Gastroenterology and Hepatology). Patients from the department’s outpatient clinic were included in the study if they were at least 18 years old, gave written informed consent and had a history of continuous PPI use for at least 6 months. Exclusion criteria were active infections at time of inclusion, antibiotic therapy including prophylactic therapy within 14 days of inclusion, inflammatory bowel disease, consumption of pre-, pro- or symbiotics other than the study product, and concomitant diseases or circumstances that suggest that the patient is not eligible. A daily dose of 4g of a multispecies probiotic (Institute Allergosan, Graz, Austria/ Winclue Probiotics, Amsterdam, The Netherlands) was administered to all patients for three months followed by a three-month observation period without intervention. The study product contained 12 strains (Bacillus coagulans W183, Bacillus subtilis W201, Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus rhamnosus W71, Lactobacillus salivarius W24, Lactococcus lactis W19, Propionibacterium freudenreichii W200) in a total concentration of 2 × 10^9 cfu/g. The probiotic strains were selected based on their capacity to inhibit pathogens (Salmonella, E. coli and C. difficile), improve intestinal barrier function and the ability to produce vitamins. The bacteria were embedded in a prebiotic mixture of corn starch, maltodextrin, fructose-oligosaccharide P6, inulin P2 and vegetable protein. Patients dissolved the powder in 125 ml of water and drank the suspension after a 10 minute activation period.

Primary endpoint was the normalization of calprotectin levels in stool; this was also the basis for the sample size calculation. Secondary endpoints were gut permeability (assessed by faecal zonulin levels, serum levels lipopolysaccharide, lipopolysaccharide-binding protein and sCD14), microbiome composition, gastrointestinal and health-related quality of life (assessed by gastrointestinal quality of life index (GIQLI) and Short Form (SF)-36 questionnaires), vitamin B12 levels and routine laboratory parameters. Dietary habits were tracked by an extensive, validated food frequency questionnaire70.

The study protocol was approved by the Research Ethics Board of the Medical University of Graz (29-552 ex 16/17) and was registered prior to the inclusion of the first patient at clinicaltrials.gov (NCT03220802, 18.07.2017). All study procedures were performed according to the Declaration of Helsinki and Good Clinical Practice. For more detailed information, the study protocol is provided as Supplementary Information.

Laboratory assessments. Commercially available ELISA were used to assess calprotectin and zonulin in stool (Immundiagnostik, Bensheim, Germany), as well as LBP and sCD14 in plasma (Hycult Biotechnology, Uden, Netherlands and R&D Systems, Abbingdon, UK, respectively). Lipopolysaccharide was measured with a cell-based detection system (Invitrogen, Toulouse, France) using an adapted protocol71. Reference values for normal calprotectin levels (<50 ng/mg) were provided by the manufacturer. Reference values for low zonulin levels (<50 ng/ml) were established in our laboratory as recommended by the manufacturer with samples from healthy volunteers with normal calprotectin levels.

Microbiome analysis. Stool samples were collected by the patients in sterile collection tubes either on the same day or the evening before the study visit. Samples were kept on 4°C until arrival at the hospital and then frozen immediately at −80°C. DNA was isolated with the MagNA Pure LC DNA Isolation Kit III (Bacteria, Fungi) (Roche, Mannheim, Germany) according to manufacturer’s instructions. Hypervariable region V1-V2 was amplified (primers: 27F-AGAGTTTGATCCTGGCTCAG; R357-CTGCTGCCTYCCGTA) and sequenced using Illumina Miseq technology (Illumina, Eindhoven, Netherlands) as described before51. Paired end reads were then joined by fastq-join tool. Primers were removed by cutadapt 1.6 and USEARCH 6.172 was used for reference based chimera detection. Open reference operational taxonomic unit picking was done with SILVA v132 when necessary. Database sequences were blasted in the NCBI database for further classification53. Clustering was performed by UCLUST54 with a 97% sequence similarity threshold. Fasttree was used to generate a phylogenetic tree. After pre-processing, an average of 68 014 (range from 36 502 to 89 457) reads per sample was available. Data was normalized by rarefaction (sampling depth: 36 502 reads). Raredfied data was used for alpha diversity assessment with Chao1 index and beta diversity assessment with redundancy analysis with one or two explanatory variables. LDA effect size (LEfSe) was used to find differentially abundant taxa on family, genus and species level. An LDA score (log10 of 2 or higher) was regarded as significant. Network analysis was done based on Spearman correlation where only positive correlations were taken into account. Data analysis was performed with QIME1.9.175 implemented on a local Galaxy instance (https://galaxy.medunigraz.at/), redundancy analysis,
network analysis and linear discriminant analysis effect size (LEfSe) were done in the web-based software Calypso 8.84 (http://cgenomine.net/wiki/index.php/Calypso)\textsuperscript{75}.

In order to establish that patients included in the study show PPI-associated dysbiosis, an already published cohort\textsuperscript{7} of 19 healthy controls without PPI intake was used to compare the composition of the microbiome between the groups. A brief description of the control cohort is given in Table S2.

**Statistical analysis.** All patients who finished the study protocol were included in the analysis. Count data is presented as absolute numbers and percentages, continuous data as means and 95% confidence intervals. Differences between values before and after intervention/follow up were evaluated with Wilcoxon signed-rank tests. SPSS 23 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis and the R packages “ggplot2” and “ggpubr” for visualization\textsuperscript{77–79}.

**Data availability.** Sequencing data is made publicly available at the NCBI Sequence Read Archive under the accession number PRJNA532853. All other data is shared upon reasonable request sent to the corresponding author.

Received: 28 May 2019; Accepted: 30 January 2020; Published online: 17 February 2020

**References**

1. Freedberg, D. E., Kim, L. S. & Yang, Y. X. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. *Gastroenterology* 152, 706–715, https://doi.org/10.1053/j.gastro.2017.01.031 (2017).
2. Eriksson, S., Langstrom, G., Rikner, L., Carlsson, R. & Naesdal, J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. *European journal of gastroenterology & hepatology* 7, 467–473 (1995).
3. Malfertheiner, P., Kandulska, A. & Venerito, M. Proton-pump inhibitors: understanding the complications and risks. *Nature reviews. Gastroenterology & hepatology* 14, 807–710, (2017).
4. Janarthanan, S., Ditiah, I., Adler, D. G. & Ehrnpriess, M. N. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. *The American journal of gastroenterology* 107, 1001–1010, https://doi.org/10.1038/ajg.2012.179 (2012).
5. Leonard, J., Marshall, J. K. & Moayyedi, P. Systematic review of the risk of enteric infection in patients taking acid suppression. *The American journal of gastroenterology* 102, 2047–2056, quiz 2057, https://doi.org/10.1111/j.1572-0241.2007.01275.x (2007).
6. Bavi, C. & Dupont, H. L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. *Alimentary pharmacology & therapeutics* 34, 1269–1281, https://doi.org/10.1111/j.1365-2036.2011.04874.x (2011).
7. Compare, D. et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. *European journal of clinical investigation* 41, 380–386, https://doi.org/10.1111/j.1365-2362.2010.02419.x (2011).
8. Schmulson, M. J. & Frati-Munari, A. C. Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico. *Revista de gastroenterologia de Mexico* 84, 44–51, https://doi.org/10.1016/j.rgmx.2018.02.008 (2019).
9. Marcuard, S. P., Albernez, L. & Khazanie, P. G. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). *Annals of internal medicine* 120, 211–215 (1994).
10. Heidelbaugh, J. J. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. *Therapeutic advances in drug safety* 4, 125–133, https://doi.org/10.1177/1754949313482848 (2013).
11. Cohen, M. Proton pump inhibitors may cause elevation in faecal calprotectin levels. *ISME journal* 9, 573–574, author reply 574 (2015).
12. Poullis, A., Foster, R., Mendall, M. A., Shreeve, D. & Wiener, K. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. *European journal of gastroenterology & hepatology* 15, 573–574, author reply 574 (2003).
13. Seto, C. T., Jeraldol, P., Orenstein, R., Chia, N. & Dibaise, J. K. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for *Clostridium difficile* susceptibility. *Microbiome* 2, 42, https://doi.org/10.1186/2049-2618-2-42 (2014).
14. Su, T., Lai, S., Lee, A., He, X. & Chen, S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. *Journal of gastroenterology* 53, 27–36, https://doi.org/10.1007/s00535-017-1371-9 (2018).
15. Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. *Gut* 65, 740–748, https://doi.org/10.1136/gutjnl-2015-310376 (2016).
16. Clooney, A. G. et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. *Alimentary pharmacology & therapeutics* 43, 974–984, https://doi.org/10.1111/apt.13568 (2016).
17. Bajai, J. S. et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. *Am J Physiol Gastrointest Liver Physiol* 307, G951–957, https://doi.org/10.1152/ajpgi.00268.2014 (2014).
18. Tsuda, A. et al. Influence of Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract. *Clinical and translational gastrointestinal* 6, 689, https://doi.org/10.1038/ctg.2015.20 (2015).
19. Jackson, M. A. et al. Proton pump inhibitors alter the composition of the gut microbiota. *Gut* 65, 749–756, https://doi.org/10.1136/gutjnl-2015-310861 (2016).
20. He, X., McLean, J. S., Guo, L., Lux, R. & Shi, W. The social structure of microbial community involved in colonization resistance. *The ISME Journal* 8, 564–574, https://doi.org/10.1038/ismej.2013.172 (2014).
21. Case, T. J. Invasion resistance arises in strongly interacting species-rich model competition communities. *Proceedings of the National Academy of Sciences of the United States of America* 87, 9610–9614 (1990).
22. Freedberg, D. E. et al. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. *Gastroenterology* 149, 883–885.e889, https://doi.org/10.1053/j.gastro.2015.06.043 (2015).
23. Sieczkowska, A., Landowski, P., Zagórzczon, P., Kaminska, B. & Lifschitz, C. Small Bowel Bacterial Overgrowth Associated with Persistence of Abdominal Symptoms in Children Treated with a Proton Pump Inhibitor. *The Journal of pediatrics* 166, 1310–1312, https://doi.org/10.1016/j.jpeds.2015.04.004 (2015).
24. Bele, O., Olarau, L., Dobrescu, A., Marcovici, T. & Marginean, O. Is It Useful to Administer Probiotics Together With Proton Pump Inhibitors in Children With Gastroesophageal Reflux? *Journal of neurogastroenterology and motility* 24, 51–57, https://doi.org/10.5056/jnm17059 (2018).
25. Johansson, M. L. et al. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. *Applied and environmental microbiology* 59, 15–20 (1993).
26. Lidbeck, A., Gustafsson, J. A. & Nord, C. E. Impact of Lactobacillus acidophilus supplements on the human oropharyngeal and intestinal microbiota. *Scandinavian journal of infectious diseases* 19, 531–537 (1987).
Acknowledgements
We want to thank Ingeborg Klymiuk at the Center for Medical Research in Graz for her help with the 16S rRNA gene sequencing. The study was funded by MEFOGraz (Vereinigung Forschungsförderung Meduni Graz). The study product was produced by Wincolve BV (Amsterdam, the Netherlands) and provided free of charge by Institut Allergosan (Graz, Austria). The funding institution was not involved in the study design, in the collection, analysis and interpretation of data, in the writing of the report, or in the decision to submit the article for publication.

Author contributions
A.H. analyzed the data, interpreted the results, drafted the manuscript and obtained funding. B.L. contributed to the design of the study. N.F., M.S., I.K., F.R., A.B. acquired data. V.S. designed the study, interpreted the results, drafted the manuscript and obtained funding. All authors read and approved the final version of the manuscript.

Competing interests
A.H. received travel grants from Wincolve Probiotics, outside the submitted work; V.S. received personal fees from Institut Allergosan, personal fees from Wincolve Probiotics, grants from Fresenius Kabi Austria and personal fees from Ferring, outside the submitted work; B.L., N.F., M.S., I.K., F.R., A.B. have nothing to disclose. All authors have read the journal's policy on conflicts of interest.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-59550-x.

Correspondence and requests for materials should be addressed to A.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020

63. Wilkins, T. & Sequoia, J. Probiotics for Gastrointestinal Conditions: A Summary of the Evidence. American family physician 96, 170–178 (2017).
64. Hungin, A. P. S., Mitchell, C. R., Whorwell, P., Mulligan, C. & Cole, O. Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus. 47, 1054–1070, https://doi.org/10.1111/apt.14539 (2018).
65. Ringel-Kulka, T. et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bb-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. Journal of clinical gastroenterology 45, 518–525, https://doi.org/10.1097/MCG.0b013e31820ca4de (2011).
66. Rogha, M., Esfahani, M. Z. & Zargarzadeh, A. H. The efficacy of a symbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterology and hepatology from bed to bench 7, 156–163 (2014).
67. Steenbergen, L., Sellaro, R., van Hemert, S., Bosch, J. A. & Colzato, L. S. A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain, Behavior, and Immunity 48, 258–264, https://doi.org/10.1016/j.bbi.2015.04.003 (2015).
68. Valles-Colomer, M., Falony, G. & Darzi, Y. The neuroactive potential of the human gut microbiota in quality of life and depression, https://doi.org/10.1038/s41598-017-15650-9 (2017).
69. Shi, H.-Y. et al. Responsiveness and Minimal Clinically Important Differences after Cholecystectomy: GIQLI Versus SF-36. Journal of Gastrointestinal Surgery 12, 1275, https://doi.org/10.1007/s11665-008-0526-7 (2008).
70. Haftenberger, M. et al. Relative validation of a food frequency questionnaire for national health and nutrition monitoring. Nutrition journal 9, 36, https://doi.org/10.1186/1475-2891-9-36 (2010).
71. Stadlbauer, V. et al. Structural and functional differences in gut microbiome composition in patients undergoing haemodialysis or peritoneal dialysis. Scientific reports 7, 15601, https://doi.org/10.1038/s41598-017-15650-9 (2017).
72. Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C. & Knight, R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics (Oxford, England) 27, 2194–2200, https://doi.org/10.1093/bioinformatics/btt381 (2011).
73. Coordinators, N. R. Database resources of the National Center for Biotechnology Information. Nucleic Acids Research 44, D7–D19, https://doi.org/10.1093/nar/gkv1290 (2016).
74. Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics (Oxford, England) 26, 2460–2461, https://doi.org/10.1093/bioinformatics/btq461 (2010).
75. Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nature methods 7, 335–336, https://doi.org/10.1038/nmeth.f.303 (2010).
76. Zakrzewski, M. et al. Calypso: a user-friendly web-server for mining and visualizing microbiome-environment interactions. Bioinformatics (Oxford, England) 33, 782–783, https://doi.org/10.1093/bioinformatics/btw725 (2017).
77. Kassambara, A., ggpubr: ggplot2 Based Publication Ready Plots, https://cran.r-project.org/package=ggpubr (2018).
78. Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (Springer-Verlag New York, 2009).
79. R_Core_Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria., https://www.R-project.org/ (2017).